RECURSION PHARMACEUTICALS, INC. Variable Lease, Cost
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Variable Lease, Cost of $3.94 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-25
- RECURSION PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2024-12-31 was $1.39M, a 225.76% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2024-09-30 was $704.00K, a 32.33% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2024-06-30 was $697.00K, a 39.68% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. variable lease, cost for the quarter ending 2024-03-31 was $538.00K, a 18.11% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. variable lease, cost for fiscal 2025 was $3.94M, a 18.20% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. variable lease, cost for fiscal 2024 was $3.33M, a 57.37% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. variable lease, cost for fiscal 2023 was $2.12M, a 97.76% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. variable lease, cost for fiscal 2022 was $1.07M.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.94M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.10M derived: sum of 2 quarters · filed 2026-02-25 | $2.79M derived: sum of 3 quarters · filed 2026-02-25 | $3.33M 10-K · filed 2026-02-25 |
| 2024-09-30 | $704.00K 10-Q · filed 2024-11-06 | $1.40M derived: sum of 2 quarters · filed 2024-11-06 | $1.94M 10-Q · filed 2024-11-06 | $2.37M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $697.00K 10-Q · filed 2024-08-08 | $1.24M 10-Q · filed 2024-08-08 | $1.66M derived: sum of 3 quarters · filed 2026-02-25 | $2.19M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $538.00K 10-Q · filed 2024-05-09 | $965.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.50M derived: sum of 3 quarters · filed 2026-02-25 | $2.00M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $959.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.46M derived: sum of 3 quarters · filed 2026-02-25 | $2.12M 10-K · filed 2026-02-25 |
| 2023-09-30 | $532.00K 10-Q · filed 2024-11-06 | $1.03M derived: sum of 2 quarters · filed 2024-11-06 | $1.69M 10-Q · filed 2024-11-06 | $1.99M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $499.00K 10-Q · filed 2024-08-08 | $1.16M 10-Q · filed 2024-08-08 | $1.45M derived: sum of 3 quarters · filed 2025-02-28 | $1.56M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $657.00K 10-Q · filed 2024-05-09 | $955.00K derived: sum of 2 quarters · filed 2025-02-28 | $1.06M derived: sum of 3 quarters · filed 2025-02-28 | $1.52M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $298.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $400.00K derived: sum of 2 quarters · filed 2025-02-28 | $865.00K derived: sum of 3 quarters · filed 2025-02-28 | $1.07M 10-K · filed 2025-02-28 |
| 2022-09-30 | $102.00K 10-Q · filed 2023-11-09 | $567.00K derived: sum of 2 quarters · filed 2023-11-09 | $772.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $465.00K 10-Q · filed 2023-08-08 | $669.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $204.00K 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |